{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T12:15:05Z","timestamp":1783167305779,"version":"3.54.6"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jfma.2026.06.045","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:15:37Z","timestamp":1783163737000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world analysis of autologous stem cell transplantation in primary central nervous system lymphoma using Taiwan Blood and Marrow Transplantation Registry"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1492-5219","authenticated-orcid":false,"given":"Po-Tsen","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4682-7906","authenticated-orcid":false,"given":"Pei-An","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bor-Sheng","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang-Tsai","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Jen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7099-8054","authenticated-orcid":false,"given":"Tsai-Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jfma.2026.06.045_bib1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41572-023-00439-0","article-title":"Primary central nervous system lymphoma","volume":"9","author":"Ferreri","year":"2023","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"10.1016\/j.jfma.2026.06.045_bib2","first-page":"971","article-title":"Primary central nervous system lymphoma","volume":"140","author":"Schaff","year":"2022","journal-title":"Blood, J Am Soc Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.jfma.2026.06.045_bib3","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1182\/blood-2022-163244","article-title":"Consolidation improves survival in primary central nervous system lymphoma without preference for type of high-dose methotrexate-based induction treatment regimen","volume":"140","author":"De Groot","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jfma.2026.06.045_bib4","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1038\/leu.2017.170","article-title":"High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German cooperative PCNSL study group","volume":"31","author":"Kasenda","year":"2017","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.jfma.2026.06.045_bib5","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1200\/JCO.18.00306","article-title":"Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study","volume":"37","author":"Houillier","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jfma.2026.06.045_bib6","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/s41375-022-01582-5","article-title":"Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial","volume":"36","author":"Ferreri","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.jfma.2026.06.045_bib7","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","volume":"4","author":"Ferreri","year":"2017","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.jfma.2026.06.045_bib8","doi-asserted-by":"crossref","first-page":"8089","DOI":"10.1002\/cam4.5607","article-title":"Long\u2010term outcomes of frontline intensification in primary CNS lymphoma: a real\u2010world single\u2010center experience","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.jfma.2026.06.045_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-016-2311-4","article-title":"High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma\u2014a randomized phase III trial (MATRix)","volume":"16","author":"Schorb","year":"2016","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.jfma.2026.06.045_bib10","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(23)00371-X","article-title":"High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial","volume":"11","author":"Schorb","year":"2024","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.jfma.2026.06.045_bib11","first-page":"510","article-title":"Primary central nervous system lymphoma: advances in treatment strategies","volume":"61","author":"Kondo","year":"2020","journal-title":"[Rinsho ketsueki] Japan J Clin Hematol"},{"issue":"7","key":"10.1016\/j.jfma.2026.06.045_bib12","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1001\/jamaoncol.2021.1074","article-title":"Outcomes associated with thiotepa-based conditioning in patients with primary central nervous system lymphoma after autologous hematopoietic cell transplant","volume":"7","author":"Scordo","year":"2021","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.jfma.2026.06.045_bib13","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1016\/j.clml.2018.11.018","article-title":"Autologous stem-cell transplantation for primary central nervous system lymphoma: systematic review and meta-analysis","volume":"19","author":"Alnahhas","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"22","key":"10.1016\/j.jfma.2026.06.045_bib14","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jfma.2026.06.045_bib15","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41409-022-01648-z","article-title":"Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life\u2014experience of the French network","volume":"57","author":"Schenone","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jfma.2026.06.045_bib16","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.bbmt.2019.01.020","article-title":"High-dose chemotherapy with autologous stem cell transplantation in primary central nervous system lymphoma: data from the Japan society for hematopoietic cell transplantation registry","volume":"25","author":"Kondo","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jfma.2026.06.045_bib17","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/bmt.2017.101","article-title":"High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom","volume":"52","author":"Kassam","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"22","key":"10.1016\/j.jfma.2026.06.045_bib18","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1200\/JCO.2003.05.024","article-title":"Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis","volume":"21","author":"Abrey","year":"2003","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jfma.2026.06.045_bib19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/sj.bmt.1705452","article-title":"High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group","volume":"38","author":"Colombat","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jfma.2026.06.045_bib20","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3390\/cancers15020526","article-title":"Diagnosis and treatment using autologous stem-cell transplantation in primary central nervous system lymphoma: a systematic review","volume":"15","author":"Steffanoni","year":"2023","journal-title":"Cancers"},{"issue":"13","key":"10.1016\/j.jfma.2026.06.045_bib21","first-page":"1642","article-title":"The role of autologous stem cell transplantation in primary central nervous system lymphoma","volume":"127","author":"Ferreri","year":"2016","journal-title":"Blood, J Am Soc Hematol"},{"issue":"1","key":"10.1016\/j.jfma.2026.06.045_bib22","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3324\/haematol.11771","article-title":"High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system","volume":"93","author":"Illerhaus","year":"2008","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.jfma.2026.06.045_bib23","first-page":"1403","article-title":"R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma","volume":"125","author":"Omuro","year":"2015","journal-title":"Blood, J Am Soc Hematol"},{"issue":"4","key":"10.1016\/j.jfma.2026.06.045_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.71707","article-title":"Nationwide incidence, treatment pattern, and prognosis of primary CNS lymphoma in Taiwan, 2012\u20132020: a retrospective cohort study","volume":"15","author":"Hsiao","year":"2026","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.jfma.2026.06.045_bib25","first-page":"14","article-title":"Thiotepa, Busulfan, cyclophosphamide: effective but toxic conditioning regimen prior to autologous hematopoietic stem cell transplantation in central nervous system lymphoma","volume":"11","author":"Delphine","year":"2023","journal-title":"Med Sci"},{"issue":"1","key":"10.1016\/j.jfma.2026.06.045_bib26","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.bbmt.2016.09.024","article-title":"A comprehensive assessment of toxicities in patients with central nervous system lymphoma undergoing autologous stem cell transplantation using thiotepa, busulfan, and cyclophosphamide conditioning","volume":"23","author":"Scordo","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jfma.2026.06.045_bib27","doi-asserted-by":"crossref","first-page":"1191. e1","DOI":"10.1016\/j.jtct.2024.09.015","article-title":"Comparison of thiotepa-based conditioning regimens for older adults with primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplantation","volume":"30","author":"Akhtar","year":"2024","journal-title":"Transplant Cell Therap"},{"issue":"1","key":"10.1016\/j.jfma.2026.06.045_bib28","doi-asserted-by":"crossref","first-page":"vdab007","DOI":"10.1093\/noajnl\/vdab007","article-title":"Extent of radiological response does not reflect survival in primary central nervous system lymphoma","volume":"3","author":"Van Der Meulen","year":"2021","journal-title":"Neuro-Oncol Adv"},{"issue":"12","key":"10.1016\/j.jfma.2026.06.045_bib29","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/j.bbmt.2020.08.012","article-title":"Outcomes of autologous stem cell transplant consolidation in primary central nervous system lymphoma: a Mayo clinic experience","volume":"26","author":"Khurana","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jfma.2026.06.045_bib30","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1007\/s10238-023-01182-2","article-title":"Different patterns of failure in two treatment regimens for primary central nervous system lymphoma, a retrospective analysis of 124 cases in Taiwan","volume":"23","author":"Chuang","year":"2023","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.jfma.2026.06.045_bib31","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.14382","article-title":"Favourable outcome of relapsed PCNSL among transplant eligible patients","author":"Pellonper\u00e4","year":"2025","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.jfma.2026.06.045_bib32","doi-asserted-by":"crossref","first-page":"vdae037","DOI":"10.1093\/noajnl\/vdae037","article-title":"Three-year follow-up analysis of phase 1\/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma","volume":"6","author":"Yonezawa","year":"2024","journal-title":"Neuro-Oncol Adv"},{"key":"10.1016\/j.jfma.2026.06.045_bib33","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1182\/blood-2024-201386","article-title":"Real world evidence of tirabrutinib as a salvage treatment in patients with relapsed or refractory primary central nervous system lymphoma in Taiwan: a multicenter study","volume":"144","author":"Liao","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jfma.2026.06.045_bib34","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/neuonc\/noaa145","article-title":"Phase I\/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma","volume":"23","author":"Narita","year":"2021","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.jfma.2026.06.045_bib35","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1111\/bjh.16759","article-title":"Ibrutinib in patients with relapsed\/refractory central nervous system lymphoma: a retrospective single-centre analysis","volume":"190","author":"Lauer","year":"2020","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.jfma.2026.06.045_bib36","doi-asserted-by":"crossref","first-page":"8160","DOI":"10.3390\/curroncol29110644","article-title":"Cranial radiation therapy as salvage in the treatment of relapsed primary CNS lymphoma","volume":"29","author":"Volpini","year":"2022","journal-title":"Curr Oncol"},{"issue":"7","key":"10.1016\/j.jfma.2026.06.045_bib37","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1002\/ajh.27316","article-title":"CAR T\u2010cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: real\u2010life results of the LOC network","volume":"99","author":"Choquet","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jfma.2026.06.045_bib38","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2024014373","article-title":"ICE polychemotherapy is an efficient salvage treatment in relapsed\/refractory primary central nervous system lymphoma","author":"P\u00e9rol","year":"2025","journal-title":"Blood Adv"},{"issue":"36","key":"10.1016\/j.jfma.2026.06.045_bib39","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1200\/JCO.2006.08.2941","article-title":"Primary central nervous system lymphoma: the memorial sloan-kettering cancer center prognostic model","volume":"24","author":"Abrey","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jfma.2026.06.045_bib40","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","article-title":"Prognostic scoring system for primary CNS lymphomas: the international extranodal lymphoma study group experience","volume":"21","author":"Ferreri","year":"2003","journal-title":"J Clin Oncol"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664626007023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664626007023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:15:41Z","timestamp":1783163741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664626007023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":40,"alternative-id":["S0929664626007023"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2026.06.045","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world analysis of autologous stem cell transplantation in primary central nervous system lymphoma using Taiwan Blood and Marrow Transplantation Registry","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2026.06.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}